Author(s)

Aboudou Raïmi Kpossou^1*, Jean Séhonou¹, Gbénagnon Micaël Géraud Adjigbé¹, Rodolph Koffi Vignon¹, Khadidjatou Saké Alassan², Nicolas Kodjoh³

¹Department of Gastroenterology and Hepatology, National University Hospital Center-Hubert Koutoukou Maga (CNHU-HKM), Cotonou, Benin.
²Internal Medicine Unit, University and Departmental Hospital of Borgou-Alibori, Parakou, Benin.
³Clinic Les Archanges, Sèmè Kpodji, Benin.

Background: Viral hepatitis C (HCV) is common in Benin. Untreated, it can be complicated by cirrhosis and hepatocarcinoma, which are sources of death. The objectives of this work were twofold: 1) to evaluate the effectiveness and safety of treatment with classic dual interferon pegylated alpha-2a (IFN) and ribavirin therapy in Benin, and 2) to present problems related to financial accessibility to this treatment. Methods: This was a cross-sectional, descriptive and analytical study, with a retrospective collection of data from November 1, 2010 to December 31, 2015 and prospective collection from January 1, 2016 to July 31, 2016 (7 months). We included all patients treated with IFN + ribavirin for hepatitis C at CNHU/HKM. Sustained virological response (SVR) was defined as undetectable viral load C 6 months after stopping treatment. Safety was appreciated by the search for clinical and hematological adverse effects. Results: One hundred and six patients were followed for HCV, of whom 58 (54.7%) undergoing treatment (26 under standard dual therapy and 32 under direct-acting antivirals). Of the 26 patients under-conventional dual therapy, 12 (46.1%) were genotype 1, 13 (50%) genotype 2 and one (3.9%) genotype 4. In conventional dual therapy, SVR was achieved in 15 (57.7%) patients, including the genotype 4 patient, 4 out of 12 (33.3%) genotype 1 patients, and 10 out of 13 (76.9%) for genotype 2 patients. The most common side effects with this treatment were severe asthenia (23 cases), flu-like symptoms (22 cases), weight loss (21 cases) and neutropenia (22 cases), anemia and thrombocytopenia (20 of 26 cases). The overall cost of treatment per patient was 11,800,624 FCFA for genotypes 1 and 4; and 7,835,048 FCFA for genotype 2. Conclusion: The treatment of HCV with IFN + ribavirin in Benin is effective for genotype 2. But its adverse effects are manifold and its cost is high. The switch to direct-acting antivirals (more effective, better tolerated and less expensive) was therefore necessary.

Hepatitis C, Pegylated Interferon Alpha-2a, Ribavirin, Effectiveness, Safety, Cost

Kpossou, A. , Séhonou, J. , Adjigbé, G. , Vignon, R. , Alassan, K. and Kodjoh, N. (2018) Treatment of Hepatitis C with Pegylated Interferon Alpha-2a and Ribavirin: Experience from Benin. Open Journal of Gastroenterology, 8, 275-283. doi: 10.4236/ojgas.2018.88030.